HK:2616 Cstone Pharmaceuticals

CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The company's pre-clinical and late-stage clinical products include ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; CS1001, a momoclonal antibody against programmed death ligand-1; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; CS3009, an inhibitor for the treatment of non-small lung cancer and medullary thyroid carcinoma; CS3008 used for the treatment of hepatocellular carcinoma; CS1002, a monoclonal antibody for various indications; CS1003, a monoclonal antibody against programmed death receptor; and CS3006 for the treatment of solid tumors. Its products also comprise CS3002 and CS3003 for solid tumors, as well as CS3004, CS1009, CS3005, and CS2004 for other indications. In addition, the company provides medical and biotechnological development, technical consultation, technological transfer, and corporate management and commercial information consultation services. The company has a licensing agreement with Numab Therapeutics AG for the development and commercialization of ND021, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; and a clinical collaboration with Bayer HealthCare LLC to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib. CStone Pharmaceuticals was founded in 2015 and is headquartered in Shanghai, China.

14.10 HKD
As of 06/15/2021

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  Cayman Islands
IPO date:  02/26/2019
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   16,836,021,248 HKD
Current dividend yield:   0.00%
ISIN:        KYG2588M1006
Sedol:      BHZ6573

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy